<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Cellistic 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=47033></link><description><![CDATA[Cellistic 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Mon, 04 May 2026 00:16:28 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2024/12/12_31017998_20241215132717_9804532420.png]]></url></image><language>ko-KR</language><item><title><![CDATA[BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1002874</link><description><![CDATA[TOKYO & MONT-SAINT-GUIBERT, Belgium--(Business Wire/Korea Newswire)--BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and Cellistic, a leader in advanced iPS cell therapy manufacturing, today announced a process development and manufacturing agreement to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing...]]></description><pubDate>Sun, 15 Dec 2024 13:40:00 +0900</pubDate></item><item><title><![CDATA[브라이트패스 바이오와 셀리스틱, iPSC 유래 BCMA CAR-iNKT 세포의 1상 임상시험의 공정 개발 및 제조 협력 발표]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1002875</link><description><![CDATA[도쿄/몽생기베르, 벨기에--(Business Wire/뉴스와이어)--iPS 세포 유래 자연살해 T(Natural Killer T, 이하 ‘NKT’) 세포치료제 분야의 선구자인 브라이트패스 바이오(BrightPath Bio)(도쿄증권거래소 그로스 4594호, 이하 ‘브라이트패스’)와 첨단 iPS 세포치료제 제조 분야의 선도기업인 셀리스틱(Cellistic)이 공정 개발 및 제조 계약을 체결했다고 오늘 발표했다. 브라이트패스의 새로운 동종 CAR-T 세포치료 플랫폼을 발전시켜 ...]]></description><pubDate>Sun, 15 Dec 2024 13:40:00 +0900</pubDate></item></channel></rss>